European Commission logo
English English
CORDIS - EU research results
CORDIS

Rapid monitoring of biomarkers in postoperative care

Objective

Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed in 2012. The frequency of complications after surgery is relatively high, but rapid and safe monitoring methods are missing.

MD Biomedical AB has addressed this need and developed a radically new and innovative piece of medical equipment that is gently attached on the surface of the bowel for sampling of biomakers. This makes it possible to detect complications within minutes, at an early stage of illness, and long before patient systemic indications.

The possibility of rapid counteractions improves the treatment of the patient and save health care costs.

The feasibility study comprises one work package divided in 6 tasks and shall in measurable terms assess the functional, medical, economic, and environmental effects and the deliverable is a feasibility report including a business plan.

Call for proposal

H2020-SMEInst-2014-2015

See other projects for this call

Sub call

H2020-SMEINST-1-2014

Coordinator

MD BIOMEDICAL AB
Net EU contribution
€ 50 000,00
Address
PO POX 7995
90719 UMEA
Sweden

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Norra Sverige Övre Norrland Västerbottens län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00